Literature DB >> 20552891

[Hypermethylation of the CDH1, SEPT9, HLTF and ALX4 genes and their diagnostic significance in colorectal cancer].

P A Kostin, N B Zakharzhevskaia, E V Generozov, V M Govorun, S V Chernyshov, Iu A Shchelygin.   

Abstract

Sequential treatment of bisulfate-converted DNA was used to study methylation of promoter areas of SEPT9, HLTF, ALX4 and CDH1 genes. Methylation profiles were evaluated by comparing bioptical findings on colorectal cancer (n=55) and morphologically intact areas of the large bowel (n=71). Significant differences between groups were established for SEPT9, HLTF and ALX4 genes (p < or = 10(-9)) in evaluating medium-rate methylation of CpG. Diagnostic sensitivity (Se) peaked for SEPT9 (78 +/- 7%); specificity--(86 +/- 4%) (Sp). On site CpG (position "+14"), similar findings were reported: Se=81 +/- 6%, Sp=77 +/- 5%. Therefore, CpG(14)SEPT9 may be used as a separate marker. As a result of the use of HLTF as marker on all 23 sites, Se was 67 +/- 6% and Sp--87 +/- 3%; ALX4 diagnostic sensitivity--59 +/- 6%. Specificity level was similar to those of the other genes (88 +/- 3%). Despite the role of CDH1 gene in colorectal cancer, the group-to-group differences in methylation rates were minimal. Such values of Se and Sp as 54 +/- 6% and 67 +/- 5%, respectively, could not support methylation of the CDH1 promoter area for diagnostic purposes. Therefore, combined evaluation of SEPT9, HLTF and ALX4 genes offered more advantage as far as diagnosis is concerned. Hypermethylation in two of the three genes was assumed as a criterion for diagnosis. Under such conditions, diagnostic sensitivity was 81 +/- 7% (Sp=93 +/- 3%). With such high values, the criterion has a potential of being instrumental in working out diagnostic tests for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552891

Source DB:  PubMed          Journal:  Vopr Onkol        ISSN: 0507-3758


  7 in total

Review 1.  DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer.

Authors:  Yuji Toiyama; Yoshinaga Okugawa; Ajay Goel
Journal:  Biochem Biophys Res Commun       Date:  2014-08-13       Impact factor: 3.575

Review 2.  Colorectal cancer: epigenetic alterations and their clinical implications.

Authors:  Alberto Puccini; Martin D Berger; Madiha Naseem; Ryuma Tokunaga; Francesca Battaglin; Shu Cao; Diana L Hanna; Michelle McSkane; Shivani Soni; Wu Zhang; Heinz-Josef Lenz
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-09-20       Impact factor: 10.680

Review 3.  Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.

Authors:  Fabio Coppedè; Angela Lopomo; Roberto Spisni; Lucia Migliore
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 4.  Diagnostic Performance of DNA Hypermethylation Markers in Peripheral Blood for the Detection of Colorectal Cancer: A Meta-Analysis and Systematic Review.

Authors:  Bingsheng Li; Aihua Gan; Xiaolong Chen; Xinying Wang; Weifeng He; Xiaohui Zhang; Renxiang Huang; Shuzhu Zhou; Xiaoxiao Song; Angao Xu
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

Review 5.  Abnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: A review of literature.

Authors:  Michail Galanopoulos; Nikolaos Tsoukalas; Ioannis S Papanikolaou; Maria Tolia; Maria Gazouli; Gerassimos J Mantzaris
Journal:  World J Gastrointest Oncol       Date:  2017-04-15

6.  Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis.

Authors:  Yuzhou Zhu; Tinghan Yang; Qingbin Wu; Xuyang Yang; Jianqi Hao; Xiangbing Deng; Shuo Yang; Chaoyang Gu; Ziqiang Wang
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

7.  Molecular subtypes based on DNA methylation predict prognosis in colon adenocarcinoma patients.

Authors:  Changshun Yang; Yu Zhang; Xiaoqin Xu; Weihua Li
Journal:  Aging (Albany NY)       Date:  2019-12-18       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.